IMCR · Immunocore Holdings plc · Executive Compensation
$26.41
-0.22 (-0.83%)
At close · Nov 20
Return incl. dividend (before tax)
Q4 2025 earnings call transcript
Market Cap
$1.36B
Shares
51.68M
Volume · Nov 20
546.2K
Avg daily vol (3M)
449.07K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Bahija Jallal | Chief Executive Officer | $10,885,268 |
| Travis Coy | Chief Financial Officer | $5,171,209 |
| David Berman | M.D., Ph.D. Former Executive Vice President, Head of Research & Development | $4,278,988 |
| Tina St. Leger | Chief Human Resources Officer | $1,204,261 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Bahija Jallal | Chief Executive Officer | $12,852,234 |
| David Berman | M.D., Ph.D. Executive Vice President, Head of Research & Development | $5,481,495 |
| Brian Di Donato | Former Chief Financial Officer | $3,439,339 |
| Tina St. Leger | Chief Human Resources Officer | $1,115,871 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Bahija Jallal | Chief Executive Officer | $11,678,834 |
| David Berman | M.D., Ph.D. Executive Vice President, Head of Research & Development | $4,396,622 |
| Brian Di Donato | Former Chief Financial Officer | $3,354,443 |
| Tina St. Leger | Chief Human Resources Officer | $1,039,117 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Bahija Jallal | Chief Executive Officer | $8,008,503 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Bahija Jallal | Chief Executive Officer | $34,783,285 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
|
David Berman
“Dr. Berman’s decision to resign was not the result of any disagreement between Dr. Berman and the Company or any matter relating to the Company’s operations, policies, or practices.”
|
Head of Research & Development | Resigned | 2026-01-30 |
|
Tina St. Leger
“Ms. St. Leger’s decision to resign was not the result of any disagreement between Ms. St. Leger and the Company or any matter relating to the Company’s operations, policies, or practices.”
|
Chief Human Resources Officer | Resigned | 2025-11-28 |
|
Ranjeev Krishana
“Mr. Krishana’s decision to resign was not the result of any disagreement between Mr. Krishana and the Company, management of the Company, or any other member of the Board on any matter relating to the Company’s operations, policies, or practices.”
|
member of the Board and a member of the Remuneration Committee of the Board | Resigned | 2025-11-28 |
| William Pao, M.D., Ph.D. | Class II director | Appointed | 2025-02-26 |
| Travis Coy | board of directors | Resigned | 2025-01-02 |
| Travis Coy | Executive Vice President, Chief Financial Officer and Head of Corporate Development | Appointed | 2025-01-02 |
|
Brian Di Donato
“Mr. Di Donato’s resignation was not because of any disagreement with the Company on any matter relating to the Company’s financial statements, internal controls, operations, policies or practices, including accounting principles and practices.”
|
Executive Vice President, Chief Financial Officer and Head of Strategy and principal financial officer | Resigned | 2024-08-29 |
| Ranjeev Krishana | Class I director of the Company | Appointed | 2024-05-28 |
Leadership
- Bahija Jallal CEO, Board Member
- Professor Sir John Bell Chairman
- Travis Coy CFO
- Kristine Peterson Board Member
- Professor Sir Peter Ratcliffe Board Member
- Ranjeev Krishana Board Member
- Roy S. Herbst Board Member
- Siddharth Kaul Board Member
- William Pao Board Member
- William Pao, M.D., Ph.D. Board Member
Key facts
CIK
1671927
CUSIP
45258D105
13F (30d)
150 filings
122 filers
Visit website
Investor relations